1.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395:497-506.
2.Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis : JTH 2020;18:1094- 1099.
3.Yamashita Y, Maruyama Y, Satokawa H, Nishimoto Y, Tsujino I, Sakashita H, et al. Incidence and Clinical Features of Venous Thromboembolism in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan. Circulation journal : official journal of the Japanese Circulation Society 2021 ,doi:10.1253/circj.CJ-21-0169.
4.Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood 2020;136:1342- 1346.
5.Jonsson AK, Schill J, Olsson H, Spigset O, Hagg S. Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence. CNS Drugs 2018;32:47-64.
6.Zuker-Herman R, Ayalon Dangur I, Berant R, Sitt EC, Baskin L, Shaya Y, et al. Comparison between two-point and three-point compression ultrasound for the diagnosis of deep vein thrombosis. J Thromb Thrombolysis 2018;45:99-105..
7.Ignacio de Ulibarri J, Gonzalez-Madrono A, de Villar NG, Gonzalez P, Gonzalez B, Mancha A, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp 2005;20:38-45.
8.Basic D, Hartwell TJ. Falls in hospital and new placement in a nursing home among older people hospitalized with acute illness. Clin Interv Aging 2015;10:1637-1643.
9.Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. Journal of the American Heart Association 2014;3:e001152.
10.Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-694.
11.Yamashita Y, Yamada N, Mo M. The Primary Prevention of Venous Thromboembolism in Patients with COVID-19 in Japan: Current Status and Future Perspective. Annals of vascular diseases 2021;14:1-4.
12.Horiuchi H, Morishita E, Urano T, Yokoyama K, Questionnaire-survey Joint Team on The C-rt. COVID-19-Related Thrombosis in Japan: Final Report of a Questionnaire-Based Survey in 2020. J Atheroscler Thromb 2021;28:406-416.
13.Fujiwara S, Nakajima M, Kaszynski RH, Fukushima K, Tanaka M, Yajima K, et al. Prevalence of thromboembolic events and status of prophylactic anticoagulant therapy in hospitalized patients with COVID-19 in Japan. J Infect Chemother 2021;27:869-875.
14.Masopust J, Maly R, Valis M. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci 2012;66:541-552.
15.Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost 2020, doi:10.1002/rth2.12439.
16.Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. Journal of thrombosis and haemostasis : JTH 2020;18:1743- 1746.
17.Klovaite J, Benn M, Nordestgaard BG. Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study. J Intern Med 2015;277: 573-584
18.Li JY, Wang HF, Yin P, Li D, Wang DL, Peng P, et al. Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID-
19 patients: A multicenter retrospective study. J Thromb Haemost 2021, doi:10.1111/jth.15261.
論文の公開元へ
